News and Trends 1 Jun 2017 Why Should we be Excited about the Emerging Microbiome Field? A panel of experts at Microbiome Invest in London discussed the unlimited applications of the microbiome and how emerging companies may have a big impact on healthcare. During the past 10 years, the role of bacterial populations within our own organism has been studied, revealing a huge potential to develop new types of therapeutics. “The microbiome represents a […] June 1, 2017 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jun 2017 Next-Gen Drug Conjugates Bank €46M in Series B with American Investors Bicycle Therapeutics has closed a massive fundraising round, raking in £40M (€46M) from American investors to launch clinical trials. Bicycle Therapeutics, the most recent company founded by the legendary academic-entrepreneur Greg Winter, is making a name for itself as a money magnet. Hot on the heels of a €1B deal with AstraZeneca last fall, the biotech […] June 1, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 31 May 2017 Recruitment in Biotech is Broken, Here’s How to Fix it How can changing the way your company hires, improve your business and result in better employees? Zocket brings a fresh approach to a long-standing challenge, to a systemic problem in our industry. There are multiple challenges when hiring new talent in a growing biotech. Given the rapid growth of the industry and the worldwide shortage […] May 31, 2017 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 31 May 2017 Swiss Biotech raises €10M to Target Elusive Protein Interactions in Cancer Inthera Bioscience has raised €9.6M in Series A to complete preclinical phase of its lead cancer program and expand its pipeline. Inthera Bioscience, located in Zurich, has closed a €9.6M (CHF 10.5M) Series A round led by Merck Ventures and backed by Novo Seeds and BioMedical Ventures, as well as a private investor. Members of Novo Seeds and […] May 31, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 31 May 2017 German Biotech Enters the Clinic with Next-Generation Antibody for AML Synimmune has hit the clinic with a first-in-human study of its Fc-optimized antibody FlySyn to treat patients with acute myeloid leukemia (AML). The German biotech Synimmune is developing next-generation anti-cancer antibodies to treat rare blood cancers. Its lead asset, FlySyn, is an antibody directed against the human fms-like tyrosine kinase 3 (FLT3) for the treatment of patients with […] May 31, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 31 May 2017 Swiss Biotech raises €9M to Treat Sudden Hearing Loss in Phase III Strekin has closed a Series C financing round that will fund the progression of its lead candidate for hearing loss to Phase III. Based in Basel, Strekin focuses on repurposing existing drugs by discovering new mechanisms of action. The company has now received €9.2M (CHF 10M) in Series C to fund the company’s activity until 2019 […] May 31, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 31 May 2017 Poll: Academia, Biotech or Another Career? How Industry Leaders Decided Inspired by Philip’s interview with Patrick Baeuerle, who traversed academia, entrepreneurship and finance, I collected thoughts from biotech leaders on choosing a direction. Morten Sommer Professor of Systems Biology, TU Denmark Founder of Biosyntia, AntibioTx, Microlytic There’s a lot of freedom in academia that allows you to explore things that don’t have to be immediately […] May 31, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 30 May 2017 Swiss Researchers get to the Genetic Bottom of Kidney Cancer Researchers from the University of Zurich have established a new mouse model of kidney cancer that could further our understanding of this deadly disease. Clear cell renal cell carcinoma (ccRCC) is the most common form of kidney cancer and in roughly half of the patients with this disease the tumor develops metastasis and can’t be […] May 30, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
More News! 30 May 2017 FDA Fast Tracks Muscular Dystrophy Drug backed by Woodford The FDA has handed out a Fast Track Designation to AMO Pharma for its key asset AMO-02 to treat congenital myotonic dystrophy. The British-American biotech hybrid AMO Pharma is advancing a small pipeline of drugs for rare genetic disorders. The biotech, which is backed by famous UK Investor Neil Woodford, is currently pushing its lead candidate […] May 30, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
Best in Biotech 30 May 2017 In Geneva, the Capital of Peace, 10 Biotechs Are Putting up a Fight Geneva is the largest city in French-speaking Switzerland, a financial powerhouse, home to the United Nations and known as the “Peace Capital.” Can the city’s biotech industry justify its high profile? Geneva rose to recognition as a biotech hub in 2006, when Serono sealed its acquisition by Merck in the city’s biggest-ever licensing plan. However, a late-stage […] May 30, 2017 - 7 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
Interview 29 May 2017 Meet the Founder of the UK’s Best Biotech that Discovered Humira Meet the founder of three hot British biotechs developing antibody-related technologies. Despite his interest in business, he remains an academic at heart. Sir Greg Winter is one of the biggest names in European biotech. As a Professor of Biochemistry at Cambridge University, he developed phage display technology that became the foundation of his first company in […] May 29, 2017 - 9 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 27 May 2017 “Trust me, I’m an Artist” Explores the Ethics of Biotech in Amsterdam The exhibition in Amsterdam showcases the works of ten bioartists questioning the huge complexity of ethics in the rapidly developing field of biotechnology. The Waag Society has brought together bioartists from all over Europe that explore topics like gene editing, antibiotics, human tissue culture, public health and personalized medicine. After a series of performances discussed […] May 27, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email